What Lincolnshire patients typically pay

The price of a ChondroFiller hip injection in the UK is set by the size of the cartilage defect, not by which joint is being treated. For most Lincolnshire patients considering this pathway, the starting figure is around £3,000.

Cost by defect size

• One box (focal defect up to ~3 cm²) — approximately £3,000
• Two boxes (up to ~4.5 cm²) — approximately £5,500
• Three boxes (up to ~6 cm²) — approximately £8,000
• Complex or multi-compartment hip presentations — up to approximately £9,800

Every figure above is all-inclusive: initial consultation and imaging review, real-time ultrasound guidance on the day, the collagen scaffold device itself, intravenous antibiotic cover, and a six-week follow-up appointment are all bundled in — there are no separate anaesthetist or theatre fees because no theatre is used.

Hip patients pay no injection-specific premium over knee patients at the same defect size; the tiered tariff applies across joints. One point worth separating clearly: surgical hip cartilage repair — an arthroscopic procedure performed under general anaesthetic in an operating theatre — is a different treatment entirely, and does carry a meaningful uplift, with indicative costs from around £12,740 compared with the £9,800 knee surgery starting price.

At present, no ChondroFiller injection service is publicly advertised within Lincolnshire itself, meaning most patients in the county travel to access the treatment privately.

What the all-inclusive price covers

Knowing what sits outside the quoted figure matters as much as knowing what is in it.

On the day itself, nothing is invoiced separately. The procedure takes approximately 30–45 minutes under local anaesthetic in an outpatient clinic — no operating theatre, no general anaesthetic, no overnight bed. For patients travelling from Lincolnshire, that is a practical point: most people drive themselves home or arrange a single lift, and the same-day return removes any need to book accommodation.

What may add to the total cost

• Pre-procedure imaging. MRI or X-ray confirming defect size and joint suitability is not typically included. If imaging has already been arranged through a GP or previous private consultation, no duplicate scan is needed; if not, budget for this separately.
• Physiotherapy during rehabilitation. The four-to-six-week protected-loading phase after injection carries no additional clinic fee, but guided rehabilitation with a physiotherapist — strongly advised for optimal recovery — is billed outside the package.
• Mobility aids. Crutches are standard during the protected-loading period. These are a minor but practical out-of-pocket item if not already owned.
• Insurance excess. Where private health insurance contributes to the procedural fee, any policy excess falls to the patient regardless of the approved amount.

None of these are hidden extras — they are predictable and, where relevant, worth discussing at the initial consultation.

Why the NHS does not fund this treatment

Access to a ChondroFiller hip injection through the NHS is not currently possible — and this is unlikely to change in the near term.

NICE has not issued a technology appraisal for ChondroFiller in any joint indication, whether hip or knee, and no review timeline has been publicly announced. Without a NICE appraisal, NHS trusts in England — including those serving Lincolnshire — have no commissioning pathway for the treatment. The only cartilage cell therapy the NHS does commission is autologous chondrocyte implantation (ACI), approved in 2017: a two-stage surgical procedure involving biopsy, laboratory cell culture, and re-implantation. ChondroFiller sits entirely outside that pathway.

Individual Funding Requests (IFRs) are theoretically available as an appeal route, but no published precedent for a successful ChondroFiller IFR exists in any joint; in practice, this route is unlikely to succeed at present and should not be assumed as a realistic option.

What the NHS does offer for hip cartilage damage follows a conservative-to-replacement arc: physiotherapy, anti-inflammatory medication, corticosteroid injection, and — ultimately — total hip replacement. The average NHS wait for hip replacement in England currently runs at around 27 weeks. For patients with focal hip cartilage damage who are not yet at end-stage arthritis, and who are not yet appropriate candidates for replacement, that pathway provides little in between.

Self-funded private treatment is the only current route to a ChondroFiller hip injection in the UK.

Private insurance: what it may and may not cover

Private health insurance may reduce the out-of-pocket cost of a ChondroFiller hip injection, but the coverage picture is more complicated than a simple yes or no — and one particular exclusion catches patients off guard often enough to be worth flagging at the outset.

Procedures are billed under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500. In clinical practice, approvals are most commonly reported with Bupa, Aviva, and WPA — though these are illustrative examples, not a complete list, and what one policy accepts in a given year another may decline. Approval rates are not formally published; coverage is assessed case-by-case.

The implant exclusion

Some insurers will cover the procedural and clinical fees but specifically exclude the physical collagen scaffold from the approved sum. Because the implant itself represents the largest single cost within the all-inclusive tariff, a policy that excludes it offers substantially less benefit than it might first appear to.

Before booking any appointment, patients should contact their insurer and request written pre-authorisation that names both the procedure code (W3111) and the implant device explicitly. Verbal assurances are not sufficient — the written authorisation is what protects against a later dispute.

For self-pay patients, the all-inclusive tariff is paid directly to the clinic. Anyone weighing up payment-plan options should raise this with the clinic at the initial consultation, before any appointment is confirmed.

Who the hip injection suits and who it does not

Deciding whether a ChondroFiller hip injection is relevant to your situation comes down to two things: the depth and size of the cartilage damage, and how far the hip joint has deteriorated overall.

Cartilage damage grade. The injection suits focal defects graded III or IV on the ICRS scale — that is, damage reaching down to or through the cartilage layer in a defined patch, rather than surface-level wear. Defects up to approximately 3 cm² fall clearly within the published indication; carefully selected cases up to around 6 cm² may also be considered following a specialist assessment.

Joint space. Equally important is Tönnis grade, a measure of how much the hip joint as a whole has narrowed. Tönnis grade 0 or 1 — meaning joint space is preserved or only mildly reduced — is the appropriate range for ChondroFiller injection. Tönnis grade 2 or 3, indicating substantial or advanced degeneration, is a contraindication: success rates fall markedly once the joint-wide damage reaches that stage, and patients in this category are generally better assessed for joint preservation surgery or total hip replacement.

The typical candidate is a younger or mid-life adult with focal damage arising from femoroacetabular impingement (FAI) correction or a previous hip injury — not someone with diffuse osteoarthritis throughout the joint.

When surgery is the more appropriate route. Very large or multi-compartment hip defects that exceed the injection indication may be better addressed through surgical cartilage repair — procedures such as AMIC, MACI, or osteochondral grafting — rather than the outpatient injection pathway.

What published data show. In hip studies, patients have recorded an improvement of approximately 30 points on the modified Harris Hip Score (mHHS) at 12 months. That is a clinically meaningful gain, but it is worth noting that long-term hip-specific outcome data beyond one year remain limited in published depth; the stronger evidence base still sits with the knee. A consultant assessment is needed to determine whether a patient's individual hip presentation is within the indication.

Accessing ChondroFiller hip injection from Lincolnshire

For Lincolnshire patients, the practical question is not just whether a ChondroFiller hip injection is clinically appropriate — it is how to find out without making a costly, unnecessary trip to establish that it is not.

No ChondroFiller injection service is currently advertised within Lincolnshire itself. Patients who have identified the treatment independently have, until now, faced a journey to London simply to reach an initial consultation. A local specialist assessment changes that calculation: it establishes whether the hip presentation — defect grade, Tönnis stage, lesion size — actually fits the indication before any commitment to treatment costs.

Professor Paul Lee holds outpatient hip clinics in Grantham and Sleaford. A consultation there can determine whether the ChondroFiller injection pathway is appropriate for a particular hip, whether a different injection or surgical cartilage repair route would be better suited, or whether the picture points elsewhere entirely. For patients who do proceed with treatment at a specialist centre, having local clinical support in place also avoids repeated long-distance travel during the 4–6 week protected loading phase and beyond.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.